Literature DB >> 2478619

Distinction between immunogenicity and tolerogenicity among HBcAg T cell determinants. Influence of peptide-MHC interaction.

D R Milich1, J E Jones, A McLachlan, R Houghten, G B Thornton, J L Hughes.   

Abstract

One purpose of this study was to examine the concept of T cell immunodominance employing a neonatal tolerance model. The extent to which a single T cell recognition site can represent the total T cell response to hepatitis B core Ag (HBcAg) was examined in the B10.S and B10 murine strains. It was shown that the entire B10.S T cell response to HBcAg was focused on a single immunodominant site represented by residues 120-131. This was demonstrated by exposing B10.S neonatal mice to p120-140 or p120-131, which resulted in a state of T cell tolerance to the entire HBcAg. In contrast, p120-140 contained an immunogenic T cell site for B10 mice, p129-140, but this site was nontolerogenic. Similarly, injection of p120-140 into (B10.S X B10)F1 neonatal mice resulted in tolerization of p120-131-specific, I-As-restricted T cells, but not of p129-140-specific, I-Ab-restricted T cells. The second purpose of this study was to attempt to explain the immunologic basis of an immunogenic yet nontolerogenic T cell determinant. It was shown that the p120-131 T cell site, which is immunogenic and tolerogenic in B10.S mice, could be converted into an immunogenic/nontolerogenic T cell site by a single amino acid substitution in either residue 127 or 129. Residues 127 and 129 were previously shown to be involved in interaction with MHC class II molecules (agretopic). These results demonstrated that the relative avidity of a peptide-MHC interaction can influence T cell tolerance induction. Furthermore, the results suggest that a higher threshold of peptide-MHC avidity may be required to induce T cell tolerance as compared to the threshold of peptide-MHC avidity required to immunize T cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2478619

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Nondeletional T-cell receptor transgenic mice: model for the CD4(+) T-cell repertoire in chronic hepatitis B virus infection.

Authors:  M Chen; M Sällberg; S N Thung; J Hughes; J Jones; D R Milich
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

Authors:  D R Milich; J E Jones; J L Hughes; J Price; A K Raney; A McLachlan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

3.  Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus.

Authors:  S A Litherland; X T Xie; A D Hutson; C Wasserfall; D S Whittaker; J X She; A Hofig; M A Dennis; K Fuller; R Cook; D Schatz; L L Moldawer; M J Clare-Salzler
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

4.  Immune tolerance split between hepatitis B virus precore and core proteins.

Authors:  Margaret Chen; Matti Sällberg; Janice Hughes; Joyce Jones; Luca G Guidotti; Francis V Chisari; Jean-Noel Billaud; David R Milich
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Spontaneous seroconversion in chronic hepatitis B: role of mutations in the precore/core gene.

Authors:  E Schulte-Frohlinde; G R Foster
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

6.  Hematopoietic stem-cell defects underlying abnormal macrophage development and maturation in NOD/Lt mice: defective regulation of cytokine receptors and protein kinase C.

Authors:  D V Serreze; J W Gaedeke; E H Leiter
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

7.  Autoantibody production in hepatitis B e antigen transgenic mice elicited with a self T-cell peptide and inhibited with nonself peptides.

Authors:  D R Milich; A McLachlan; A K Raney; R Houghten; G B Thornton; T Maruyama; J L Hughes; J E Jones
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

8.  Preferential recognition of hepatitis B nucleocapsid antigens by Th1 or Th2 cells is epitope and major histocompatibility complex dependent.

Authors:  D R Milich; D L Peterson; F Schödel; J E Jones; J L Hughes
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

9.  Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance.

Authors:  D C Whitacre; C J Peters; C Sureau; K Nio; F Li; L Su; J E Jones; M Isogawa; M Sallberg; L Frelin; D L Peterson; D R Milich
Journal:  Hum Vaccin Immunother       Date:  2019-12-06       Impact factor: 3.452

10.  Dysregulation of T lymphocyte proliferative responses in autoimmunity.

Authors:  Sydney K Elizer; Andrew F Marshall; Daniel J Moore
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.